Boston Scientific Investors Reminded of Class Action Deadline by Faruqi & Faruqi, LLP

Boston Scientific Investors Alerted to Class Action Deadline

Faruqi & Faruqi, LLP, a renowned national securities law firm, is currently investigating possible claims against Boston Scientific Corporation (NYSE: BSX). With the deadline for participating in a federal securities class action set for May 4, 2026, this announcement serves as a crucial reminder for investors who acquired Boston Scientific securities between July 23, 2025, and February 3, 2026.

The firm encourages affected investors to reach out and explore their legal options with Josh Wilson, a leading partner at Faruqi & Faruqi. According to the firm's analysis, this class action arises from allegations that Boston Scientific's management misled investors with false statements regarding the health of its U.S. Electrophysiology (EP) segment. Claims include that executives were aware of the unsustainable growth rate of the EP segment, yet continued to issue over-optimistic statements about the company's performance.

On February 4, 2026, Boston Scientific's disclosure of their disappointing fourth-quarter results further exacerbated the situation. The company reported a significant decline in U.S. EP sales and projections for fiscal 2026 that notably missed market expectations. As a result, the stock experienced a steep decline, plummeting $16.12, or 17.6%, to close at $75.50 per share. This unfortunate turn of events caused substantial losses to investors, as their confidence and trust in the company's future were shaken by the revelation of financial underperformance.

The court-appointed lead plaintiff in this case will represent those investors who have the most significant financial interest in the resolution of the lawsuit. Participation in the class action is open to any investor who purchased shares within the specified timeframe, and it is important to note that an investor's ability to recover does not hinge on their role as lead plaintiff.

Faruqi & Faruqi also extends an invitation to any individual with pertinent information regarding Boston Scientific's practices, including former employees and whistleblowers, to come forward. Investors seeking to learn more about this class action should visit Faruqi & Faruqi or contact Josh Wilson directly at 1-877-247-4292 or 1-212-983-9330 (Ext. 1310).

This situation underscores the importance of vigilance among investors in the rapidly evolving market landscape. As we await the developments surrounding this lawsuit, potential plaintiffs are advised to act promptly to ensure their rights are preserved.

Follow Us For More Updates: Stay tuned for further announcements and insights from Faruqi & Faruqi on LinkedIn, Twitter, and Facebook. Remember, the law firm, known for recovering significant amounts for investors, operates on a no-win, no-fee basis, further solidifying its commitment to justice for their clients and the protection of public interest.

Disclaimer: This article serves as a reminder and does not constitute legal advice. Investors are encouraged to consult with their own legal advisors regarding their specific circumstances.